Regeneron also purchased rights to the collaboration's PD-1 antibody Libtayo, which could serve as a foundation for future oncology combination regimens. Eylea has become the leading franchise in ...

Regeneron continues to deliver growth on top/bottom line in the near to longer-term with Dupi and Libtayo, the analyst tells investors in a research note.

Sales of oncology drug, Libtayo, also missed estimates. Shares are trading down in response to lower-than-expected results. Regeneron’s shares have lost 14.1% year to date compared with the ...

TARRYTOWN, N.Y., April 29, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals ... to the FDA and a regulatory application in the EU for Libtayo (cemiplimab) in adjuvant CSCC based upon data ...

Regeneron aims to advance cancer treatments through innovative research and partnerships while emphasizing the significance of their PD-1 inhibitor, Libtayo, in ongoing clinical trials.

The company announced 27 abstracts at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting ...

Shares of Regeneron Pharmaceuticals (NASDAQ ... The standard version of the anti-VEGF intravitreal injection delivered $1.4B in net product sales for the company in Q1, indicating a ~29% YoY ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull down the drugmaker. Over the first three months of 2025, Regeneron's ...

Q1 earnings and revenue miss expectations, mainly due to falling EYLEA sales. Stock rises on optimism around new drug approvals, pipeline progress, and upcoming FDA decisions. Get prepared for the ...